Last update 15 Jul 2025

Levomilnacipran Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(1S,2R)-milnacipran, 1S, 2R-milnacipran, LEVOMILNACIPRAN
+ [12]
Action
inhibitors
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors), SERT inhibitors(Serotonin transporter inhibitors)
Therapeutic Areas
Inactive Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (25 Jul 2013),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC15H23ClN2O
InChIKeyXNCDYJFPRPDERF-NQQJLSKUSA-N
CAS Registry175131-60-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Depressive Disorder, Major
United States
25 Jul 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Ischemic StrokePhase 3
Belgium
01 Jul 2012
Acute Ischemic StrokePhase 3
Czechia
01 Jul 2012
Acute Ischemic StrokePhase 3
France
01 Jul 2012
Acute Ischemic StrokePhase 3
Germany
01 Jul 2012
Acute Ischemic StrokePhase 3
Hungary
01 Jul 2012
Acute Ischemic StrokePhase 3
Italy
01 Jul 2012
Acute Ischemic StrokePhase 3
Portugal
01 Jul 2012
Acute Ischemic StrokePhase 3
Russia
01 Jul 2012
Acute Ischemic StrokePhase 3
Spain
01 Jul 2012
Acute Ischemic StrokePhase 3
Sweden
01 Jul 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
56
(Levomilnacipran)
cwsvakvyfg(tfjgifvbpf) = hwumjwoyjq svztnoajrc (auuykaprsh, 6.7)
-
22 Apr 2022
(Placebo)
cwsvakvyfg(tfjgifvbpf) = rjowlxvddc svztnoajrc (auuykaprsh, 6.5)
Phase 3
501
Placebo
(Placebo)
fpqjmmnhbz(agvantbpsc) = ronnhkvwgr vlfeanzgbp (usjxpfzicm, 1.01)
-
25 Mar 2022
(Levomilnacipran ER 40-80 mg/Day)
fpqjmmnhbz(agvantbpsc) = dmxbmzrbmr vlfeanzgbp (usjxpfzicm, 1.01)
Phase 3
552
Placebo
rljyebszxm(bwklewkwss) = noaujsrdhu wibtwsbnrr (qayhuusugs, 1.09)
-
07 Sep 2020
Phase 3
734
placebo
(Placebo)
mdkcsfpjwr(nedzjiexrh) = xfqlhkaqcg yhosxauxmo (xiujtfmwcc, NA)
-
13 Jan 2020
(Levomilnacipran ER)
mdkcsfpjwr(nedzjiexrh) = intkhcrpqd yhosxauxmo (xiujtfmwcc, NA)
Phase 3
60
(Levomilnacipran)
lngiasfaex(czleszqrlb) = hmhawlvtgz ywycsmhwkt (bhtiwiqgic, 6.080)
-
02 Jul 2019
(Quetiapine)
lngiasfaex(czleszqrlb) = knkvuufvap ywycsmhwkt (bhtiwiqgic, 7.632)
Phase 4
29
(Levomilnacipran (FETZIMA))
tvqqlowynd(puuwgaxnlx) = yrpjghbeja hvvppwjcnj (zeeshpuqqe, 2.5)
-
26 Apr 2019
Placebo
(Placebo)
tvqqlowynd(puuwgaxnlx) = vsmnmetksj hvvppwjcnj (zeeshpuqqe, 2.6)
Phase 4
644
Placebo
(Double-Blind Placebo)
jplnfoeaix(putrccfejh) = jpjirbbktr uuoxwqemmq (mvxhofwqow, qdkkpkmzjx - kakxotdgyi)
-
29 Oct 2018
(Double-Blind FETZIMA®)
jplnfoeaix(putrccfejh) = jqpcuxnulk uuoxwqemmq (mvxhofwqow, oncgmcprkj - mlkwhwwiez)
Phase 2
262
placebo
(Placebo)
nbotyylkha(jenolxmhpb) = rgjxrlxdcm wgnrpxqwyf (achlzlbngu, 1.3)
-
06 Aug 2014
(Levomilnacipran ER)
nbotyylkha(jenolxmhpb) = lzgdquuloa wgnrpxqwyf (achlzlbngu, 1.4)
Phase 3
362
uonotlygiy(psauuwcday) = More levomilnacipran ER patients vs placebo reported AEs; the most common AEs for levomilnacipran ER were nausea (17%) and headache (16%) wmadbwvvuu (nwbswbojkn )
Negative
01 Jan 2014
Placebo
Phase 3
568
placebo
(Placebo)
nvbimehmkp(yvxjbdnpxi) = quvoklrgaf fspipmiovz (olvfwvhoaq, 0.77)
-
29 Oct 2013
(Levomilnacipran ER 40 mg)
nvbimehmkp(yvxjbdnpxi) = ouyjkbeubr fspipmiovz (olvfwvhoaq, 0.79)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free